Icatibant Ratiopharm

Icatibant acetate, the active ingredient in Icatibant Ratiopharm, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and II in patients with confirmed HAE. GNH USA supplies Icatibant Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Icatibant Ratiopharm acts on the bradykinin pathway to relieve hereditary angioedema attacks. - Hereditary angioedema type I: rapidly reduces swelling during acute episodes. - Hereditary angioedema type II: alleviates symptoms of sudden edema. - Bradykinin‑mediated angioedema: blocks bradykinin‑driven vascular leakage, improving airway patency.

Icatibant Ratiopharm may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Injection site erythema: redness around the injection area. - Injection site swelling: localized edema. - Headache: transient headache episodes. - Nausea: occasional feeling of nausea. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema at injection site: extensive swelling that may compromise local tissue. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases. - Severe injection site necrosis: tissue death at the injection site.

Before using Icatibant Ratiopharm, consider the following safety measures. - Hypersensitivity assessment: avoid use in patients with known allergy to icatibant or formulation components. - Airway monitoring: observe for signs of airway obstruction during acute attacks. - Concomitant bradykinin antagonists: do not combine with other B2 receptor blockers. - Renal or hepatic impairment: use with caution; adjust monitoring as clinically indicated. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Ratiopharm has limited drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid): - Other bradykinin B2 receptor antagonists: concurrent use may lead to excessive blockade. - ACE inhibitors: may increase bradykinin levels and alter therapeutic response.

Moderate Interactions (Monitor Closely): - Angiotensin receptor blockers (ARBs): monitor for additive effects on blood pressure. - Diuretics: observe for changes in fluid balance. - Immunosuppressants: watch for altered immune response at injection site.